Abstract: The invention relates to novel 2,5-diaminotetralines of the formula: ##STR1## wherein R1, R2, R3 and R4 are defined herein, processes for preparing them and their use in pharmaceutical compositions. The novel 2,5-diaminotetralines are useful in treating diseases caused by disorders of the dopaminergic systems.

Abstract: A method of determining the total fibrinolytic activity in plasma, is characterized in thata) a quantity of fibrin sufficient to produce turbidity is added to a dilute platelet poor plasma sample or is produced in situ and the time dependent change in turbidity or the time-dependent formation of fibrin cleavage products is measured; orb) a chromogenic plasmin substrate and a quantity of fibrin, fibrinogen cleavage products or an enzyme which produces fibrin in situ, insufficient to produce turbidity, is added to a dilute platelet poor plasma sample and the time dependent color formation is measured.

Abstract: The invention relates to new diazephines of the formula ##STR1## wherein R.sup.1, R.sup.2 and R.sup.3 are as defined herein, processes for preparing them and their use as pharmaceutical compositions useful for treating PAF-induced disease.

Abstract: Disclosed are new cyclic amine derivatives of the formula I ##STR1## wherein the substituents are defined in the specification. These compounds are useful as for treating sinus tachycardia.

Abstract: A process for preparing 1,3-dipropyl-8-(3-oxocyclopentyl)-xanthine.

Abstract: Pharmacologically active R(-) 3-quinuclidinol derivatives are described which are muscarinic receptor blocking agents useful for the treatment of gastrointestinal and respiratory tract disorders of the following formula (I) ##STR1## wherein R represents a linear or branched lower alkyl group, a cycloalkyl-C.sub.1-2 alkyl or an aralkyl group, or it is absent;X represents the anion of an organic or inorganic acid, or it is absent, when R is absent;R.sub.1 represents H, a linear or branched lower alkyl group or an acyl group of the type R.sub.2 --CO, in which R.sub.

Abstract: A method for treating inflammation in a patient which comprises administering to the patient a therapeutically effective amount of a compound of the formula: ##STR1## wherein A and R.sub.1 -R.sub.6 are defined herein.

Abstract: An improved process for the preparation of D,L-Lactide which can be used directly in polymerization reactions.

Abstract: Disclosed herein are cyclic peptide derivatives of the formula ##STR1## wherein A is absent or the tripeptide radical Thr.rarw.Gly.rarw.Ala, R.sup.1 is benzyl or benzyl monosubstituted at position 4 of the aromatic ring with halo, hydroxy, lower alkyl or lower alkoxy, R.sup.2 and R.sup.4 each independently is hydrogen or lower alkyl, R.sup.3 is lower alkyl or lower alkyl monosubstituted with a hydroxy, R.sup.5 is lower alkyl, Y is oxo or thioxo and Z is hydroxy or NR.sup.6 R.sup.7 wherein R.sup.6 and R.sup.7 each independently is hydrogen or lower alkyl. The derivatives are useful for treating herpes infections.

Abstract: Cyclophanes of the general formula ##STR1## wherein X.sub.1, X.sub.2, A, R and R.sub.1 to R.sub.4 are as defined herein, the enantiomers, diastereomers and addition salts thereof and, more particularly, for pharmaceutical use, the physiologically acceptable addition salts thereof, which have pharmacological properties such as lowering blood pressure, dilating the coronary blood vessels and a mild heart rate lowering activity, pharmaceutical compositions which contain these compounds and processes for preparing them.

Abstract: The invention relates to new 2-hydroxy-n-propylamines of the formulaR.sub.1 --O--CH.sub.2 --CHOH--CH.sub.2 --NH--A--R.sub.2 (I)whereinR.sub.1, R.sub.2 and A are defined as in claim 1, the tautomers, enantiomers and acid addition salts thereof, particularly for pharmaceutical use the physiologically acceptable acid addition salts thereof with inorganic or organic acids, which have valuable pharmacological properties, more particularly a simultaneous cardiotonic and .beta.-blocking activity, and the use thereof as pharmaceutical compositions and processes for preparing them.

Abstract: By using .sub..alpha. -mimetics, particularly compounds of general formulae I to III and the compounds listed in Table I, as feed additives in fattening animals, it has surprisingly been possible to improve the daily weight gain, the utilization of fodder and the ratio of muscle to fat in favor of the proportion of muscle and protein.

Abstract: Disclosed herein are peptide derivatives which inhibit the activities of human immunodeficiency virus (HIV) protease and renin. The peptide derivatives can be represented by general formula R.sup.1 --R.sup.2 --Y--R.sup.3 --R.sup.4 wherein R.sup.1 is a derived amino acid based on an O.sup.4 -(carboxymethyl)-tyrosyl residue, R.sup.2 and are amino acid or analogous amino acid residues (R.sup.3 may optionally be absent), Y is a non-peptide linking unit, e.g. statyl, and R.sup.4 is [--NR.sup.17 CHR.sup.18 --C(O)].sub.p --Z wherein R.sup.17 is hydrogen or lower alkyl, R.sup.18 is an amino acid or analogous amino acid side chain, p is zero or one and Z is a terminal group (e.g. hydroxy or amino), or R.sup.4 is --NR.sup.17 CR.sup.18 (R.sup.21)CH.sub.2 OH wherein R.sup.17 and R.sup.18 are as noted hereinabove and R.sup.21 is hydrogen, lower alkyl or hydroxy(lower)alkyl. The derivatives are useful as agents for combatting HIV infections and for treating renin-associated hypertension and congestive heart failure.

Abstract: There is described a process for the simultaneous chemical and biological elimination of solid and liquid waste and apparatus for performing this process in the form of a loop reactor corresponding to FIG. 1 in conjunction with a specially designed nozzle which ensures an intimate mixing of substrate with air and the spraying-in of oxidizing agents while permitting only a short contact time between the oxidizing agents and the substrate.

Abstract: Novel compounds of the general formula ##STR1## which have antitussive activity, wherein R.sub.1 -R.sub.4 are as defined herein.

Abstract: A resorbable osteosynthesis device consisting of: 1) a resorbable plate, in which the side of the plate facing the bone is coated with calcium phosphate and/or hydroxyl apatite; and 2) preferably, a resorbable fixing device consisting of a threaded bolt which is optionally coated with calcium phosphate and/or hydroxyl apatite, and a nut which can be fitted onto the threaded bolt.

Abstract: Compounds of the formula (I) ##STR1## wherein R represents H or C.sub.1-6 alkyl;R.sub.1 and R.sub.2 represent H, halogen, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, C.sub.1-6 alkythio, C.sub.1-6 alkoxycarbonyl, carboxyl, hydroxy, nitro, cyano, optionally C.sub.1-4 alkyl mono- or disubstituted carbamoyl, optionally C.sub.1-4 alkyl mono- or disubstituted amino, C.sub.1-6 acylamino, C.sub.1-4 alkoxy carbonylamino, C.sub.1-6 alkylsulphynyl, C.sub.1-6 alkylsulphonyl or C.sub.1-6 acyl;R.sub.3 represents H, C.sub.1-6 alkyl, aryl or aralkyl, or it may be absent;A represents CO or C.dbd.S;E represents nitrogen;D represents CO or CR.sub.4 R.sub.5 when the E--D bond is single, or D is C--R when the D--E bond is double, in which R.sub.4 represents H, C.sub.1-6 alkyl, aryl, aralkyl, hydroxy or C.sub.1-4 alkoxy and R.sub.5 represents H;X represents oxygen or N--R, or it is absent;Y represents a basic group selected from: ##STR2## in which n is 2 or 3; p is 0 or 1 at the same time or not; q is 0,2 or 3; R.sub.6 and R.sub.

Abstract: Disclosed are novel pyridodiazepines. These compounds, as well as certain known 5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-ones are useful in the treatment of AIDS, ARC and related disorders associated with HIV infection.

Abstract: Novel aqueous oxytetracycline compositions comprising oxytetracycline, polyethylene glycol with a mean molecular weight of 400, and magnesium oxide. These compositions have good clarity and low viscosity.

Abstract: Disclosed herein are peptides of the formulaY--R.sup.1 --R.sup.2 --R.sup.3 --R.sup.4 --R.sup.5 --R.sup.6 --Zwherein R.sup.1 to R.sup.5 are designated amino acid residues; R.sup.6 is Phe, homoPhe or an amino acid residue derived from 2-amino-3-cyclohexylpropionic acid, 2-amino-3-(4-(lower alkoxy)phenyl) propionic acid or 2-amino-3-(4-halophenyl)propionic acid; Y is Phe, desamino-Phe, (lower alkanoyl)-Phe, p-haloPhe, Tyr, desamino-Tyr or (lower alkanoyl)-Tyr, or Y is the decapeptide radical W--Val--R.sup.7 --Ser--R.sup.8 --R.sup.9 --Thr--Glu--R.sup.10 --Ser--Phe wherein W is hydrogen or lower alkanoyl and R.sup.7 to R.sup.10 are designated amino acids residues, or Y is a fragment of the decapeptide radical wherein from one to nine of the amino acid residues (i.e. Val to Ser) may be deleted serially from the amino terminus of the decapeptide radical; and Z is hydroxy, amino, lower alkylamino or di(lower alkyl)amino.